• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Arcutis Inducement Grants Under Nasdaq LR 5635(c)(4)

    GLOBENEWSWIRE

    Arcutis’ ZORYVE® Awarded Best Eczema Treatment by Glamour

    GLOBENEWSWIRE

    Arcutis Announces Q3 2024 Financial Results & Business Update

    GLOBENEWSWIRE

    Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq

    GLOBENEWSWIRE

    Arcutis Presents Positive Data For ZORYVE® In Atopic Dermatitis

    GLOBENEWSWIRE

    Arcutis Drug Recieves Canada Approval to Treat Seborrheic Dermatitis

    GLOBENEWSWIRE

    Arcutis Reports Inducement Grants Under Nasdaq LR 5635(c)(4)

    GLOBENEWSWIRE

    FDA Accepts Arcutis’ Application for ZORYVE Foam for Scalp Psoriasis

    GLOBENEWSWIRE

    Zoryve Cream 0.15% Shows Improvement in Atopic Dermatitis Patients

    GLOBENEWSWIRE

    Arcutis Announces Publication Of ZORYVE® Cream Pivotal Results

    GLOBENEWSWIRE

    Arcutis Completes Enrollment Of Phase 1b Alopecia Study

    GLOBENEWSWIRE

    Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq

    GLOBENEWSWIRE

    Arcutis Announces Positive Results For Roflumilast Cream In Children

    GLOBENEWSWIRE

    Arcutis to Present at the Morgan Stanley 22nd Global Healthcare Conference

    GLOBENEWSWIRE

    Arcutis Announces Q2 2024 Financial Results And Business Update

    GLOBENEWSWIRE

    Atopic dermatitis treatment sees promising future with new drug approvals

    EXPRESSPHARMA

    Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule

    GLOBENEWSWIRE

    Arcutis To Report Q2 2024 Results On August 14

    GLOBENEWSWIRE

    Arcutis Launches ZORYVE® Cream For Atopic Dermatitis Treatment

    GLOBENEWSWIRE

    Arcutis Announces ZORYVE® Co-Promote Agreement With Kowa Pharma

    GLOBENEWSWIRE

    Arcutis Submits sNDA For ZORYVE Foam For Scalp And Body Psoriasis

    GLOBENEWSWIRE

    Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL

    GLOBENEWSWIRE

    FDA Approves Atopic Dermatitis Label Expansion for Arcutis’ Zoryve Cream

    PRESS RELEASE

    Arcutis Updates On Roflumilast Cream SNDA For Atopic Dermatitis

    GLOBENEWSWIRE

    FDA Approves Arcutis ZORYVE Cream For Atopic Dermatitis Treatment

    GLOBENEWSWIRE

    Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule

    GLOBENEWSWIRE

    Arcutis Presents Roflumilast Cream Data For Atopic Dermatitis At Conference

    GLOBENEWSWIRE

    Arcutis Bio: Reports Nasdaq Inducement Grants

    GLOBENEWSWIRE

    Arcutis: Abstracts/Oral At Alopecia, Vitiligo, Eczema Conference

    GLOBENEWSWIRE

    Arcutis to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

    GLOBENEWSWIRE

    Arcutis Announces Q1 2024 Financial Results, Business Update

    GLOBENEWSWIRE

    Expert Panel Validates ZORYVE Topical Foam For Seborrheic Dermatitis Across Hair

    GLOBENEWSWIRE

    Arcutis Reports Nasdaq Listing Rule Inducement Grants

    GLOBENEWSWIRE

    Arcutis Q1 2024 Results & Call on May 14

    GLOBENEWSWIRE

    Arcutis Biotherapeutics appoints new CFO to bolster commercial operations

    PRESS RELAESE

    Arcutis Appoints David Topper as Chief Financial Officer

    GLOBENEWSWIRE

    Arcutis Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference

    GLOBENEWSWIRE

    Arcutis Promotes Todd Tucker to Chief Human Resources Officer

    GLOBENEWSWIRE

    Arcutis Presents Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast

    GLOBENEWSWIRE

    Arcutis Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    MORNING STAT

    Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis

    GLOBENEWSWIRE

    Arcutis Announces Closing of Public Offering of Common Stock

    GLOBENEWSWIRE

    Arcutis to Present at the TD Cowen 44th Annual Health Care Conference

    GLOBENEWSWIRE

    Arcutis and Sato Announce Strategic Collaboration

    GLOBENEWSWIRE

    Arcutis Announces Proposed Public Offering

    GLOBENEWSWIRE

    Arcutis Announces Pricing of $150 Million Public Offering

    GLOBENEWSWIRE

    Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results

    GLOBENEWSWIRE

    Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results

    GLOBENEWSWIRE

    Arcutis Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    Arcutis to Present at Guggenheim Healthcare Talks “ 6th Annual Conference

    GLOBENEWSWIRE

    Journal of the American Academy of Dermatology Publishes ZORYVE Results

    GLOBENEWSWIRE

    ZORYVE for the Treatment of Seborrheic Dermatitis Launches in USA

    GLOBENEWSWIRE

    Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% According to New Data from Phase 3 Program

    GLOBENEWSWIRE

    ZORYVE Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids

    GLOBENEWSWIRE

    Arcutis` Zoryve has snagged a 2nd dermatology nod from FDA

    FIERCE PHARMA

    Arcutis Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    FDA Accepts Arcutis™ Supplemental New Drug Application for Roflumilast Cream

    GLOBENEWSWIRE

    Arcutis Announces Third Quarter 2023 Financial Results

    GLOBENEWSWIRE

    Arcutis Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.